Pancreatic cancer drug daraxonrasib from Revolution Medicines succeeds in trial

Pancreatic cancer, illustration Nemes Laszl | Science Photo Library | Getty Images Revolution Medicines‘ drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, almost doubling the typical length of survival and slashing the risk of death by 60% versus chemotherapy, the company said Monday. RevMed said its daily pill, daraxonrasib, met all…

Read More

Goldman Sachs (GS) earnings 1Q 2026

Goldman Sachs on Monday posted first-quarter results that topped expectations on record equities trading results and higher-than-expected investment banking revenue. Here’s what the company reported: Earnings: $17.55 per share vs. $16.49 LSEG estimate Revenue: $17.23 billion vs. $16.97 billion expected The bank said profit climbed 19% from the year-earlier quarter to $5.63 billion, or $17.55…

Read More